{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rhinoconjunctivitis&page=2",
    "query": {
      "condition": "Rhinoconjunctivitis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rhinoconjunctivitis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T08:28:26.536Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02557633",
      "title": "A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Grass MATA MPL 10200",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA MPL 18200",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergy Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 2,
      "location_summary": "Neptune City, New Jersey • Newark, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02557633"
    },
    {
      "nct_id": "NCT00421655",
      "title": "A Trial of Grazax in Subjects With Hayfever",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergy"
      ],
      "interventions": [
        {
          "name": "Grazax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ALK-Abelló A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 329,
      "start_date": "2006-12",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421655"
    },
    {
      "nct_id": "NCT00411606",
      "title": "Normal Values of Facial Thermography",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy",
        "Allergy",
        "Allergic Rhinoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "Thermography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "West Penn Allegheny Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "7 Years to 70 Years"
      },
      "enrollment_count": 300,
      "start_date": "2006-12",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2009-04-06",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00411606"
    },
    {
      "nct_id": "NCT00955825",
      "title": "Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Rhinitis Due to Grass Pollens"
      ],
      "interventions": [
        {
          "name": "300 IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stallergenes Greer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 473,
      "start_date": "2008-10",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2016-05-19",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 19,
      "location_summary": "Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more",
      "locations": [
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ypsilanti",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955825"
    },
    {
      "nct_id": "NCT01966224",
      "title": "A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Rhinoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Immunomic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "63 Years",
        "sex": "ALL",
        "summary": "18 Years to 63 Years"
      },
      "enrollment_count": 17,
      "start_date": "2013-09",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-30",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01966224"
    },
    {
      "nct_id": "NCT03887026",
      "title": "Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Rhinitis",
        "Allergic Rhinoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "Norketotifen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emergo Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 36,
      "start_date": "2019-04-01",
      "completion_date": "2019-05-29",
      "has_results": false,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03887026"
    },
    {
      "nct_id": "NCT01398137",
      "title": "Ragweed Observational Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ragweed Allergy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Circassia Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2011-07",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2011-10-27",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 10,
      "location_summary": "Owensboro, Kentucky • Minneapolis, Minnesota • Plymouth, Minnesota + 7 more",
      "locations": [
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "Rolla",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01398137"
    },
    {
      "nct_id": "NCT00574379",
      "title": "Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis",
        "Hay Fever",
        "Allergic Conjunctivitis",
        "Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Bilastine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Faes Farma, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 805,
      "start_date": "2007-12",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 13,
      "location_summary": "Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Kerrville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574379"
    },
    {
      "nct_id": "NCT01620762",
      "title": "Phase III Cat-PAD Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rhinoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "Cat-PAD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Circassia Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 1408,
      "start_date": "2012-10",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 52,
      "location_summary": "Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Eagle",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01620762"
    },
    {
      "nct_id": "NCT03931993",
      "title": "A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Placebo comparator",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA MPL",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergy Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-01-16",
      "completion_date": "2017-04-27",
      "has_results": false,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-06-26T08:28:26.536Z",
      "location_count": 4,
      "location_summary": "Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more",
      "locations": [
        {
          "city": "Edison",
          "state": "New Jersey"
        },
        {
          "city": "Ocean City",
          "state": "New Jersey"
        },
        {
          "city": "Springfield",
          "state": "New Jersey"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03931993"
    }
  ]
}